Meso-zeaxanthin Ocular Supplementation Trial (MOST)
Completed
- Conditions
- Age-related macular degeneration (AMD)Eye DiseasesOther retinal disorders
- Registration Number
- ISRCTN60816411
- Lead Sponsor
- Macuvision Europe Limited (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Any race
2. Male or female
3. Aged 18 to 60 years
4. No presence of ocular pathology
5. Visual acuity of at least 6/18 in the study eye
Exclusion Criteria
1. Outside age range 18 to 60 years
2. Pregnancy
3. Presence of ocular pathology
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MP optical density (including its entire spatial profile), as measured by heterochromatic flicker photometry [HFP]. <br><br>Primary and secondary outcome measures will be carried out at baseline, three, six and nine months.
- Secondary Outcome Measures
Name Time Method 1. Assessment of retinal sensitivity using microperimetry<br>2. Serum L and Z (including MZ) concentrations as measured by high-performance liquid chromatography [HPLC] <br>3. Comparison of MP optical density values measured using the validated gold standard customised HFP device (Densitometer™) to MP optical density values obtained using a MP screening device (MacuScope™)<br><br>Primary and secondary outcome measures will be carried out at baseline, three, six and nine months.